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Interleukin (IL)-33 (IL-1F11) is the newest member of the IL-1Family of cytokines and has been best characterized as
a potent inducer of T helper (Th)2 immune responses. Increasing evidence, however, indicates that IL-33 also
represents an important mediator of mucosal healing and epithelial restoration and repair. As such, IL-33 follows
the trend of several innate-type cytokines, including members of the IL-1Family (for example, IL-1α, IL-1β, and IL-18),
that possess dichotomous roles of inducing a potent proinflammatory response, while also promoting protection
and the return to immune homeostasis. This dual function is best depicted in the gut mucosa and is dependent
upon the immunological/genetic status of the host and/or the type and phase of the ongoing inflammatory
process. IL-33 has also been described as a prototypic ‘alarmin’ that has the ability to signal local, innate immune
responses of trauma or infection in an effort to mount an effective, physiologic inflammatory reaction to induce
mucosal healing and restore normal gut equilibrium. Finally, several recent studies have reported the role of IL-33
during fibrogenesis as fibrosis is commonly thought to occur as the end stage of dysregulated wound healing
wherein chronic tissue damage is paired with uncontrolled activation of mesenchymal cells. Taken together, aside
from its established function of promoting potent Th2 immune responses, IL-33 is emerging as an important
cytokine for the induction of mucosal healing and restoration of intestinal homeostasis, as well as playing a central
role in fibrosis and wound repair. The present review will focus on what is currently known regarding IL-33’s role in
gut mucosal wound healing and fibrosis, as well as touch on its potential contribution to tumorigenesis and
GI-related cancer, an alternate outcome of dysregulated epithelial proliferation.
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repair, Intestinal fibrosis, TumorigenesisReview
Introduction
The role of interleukin (IL)-1 and its related cytokine
family members is well established in the pathogenesis
of several autoinflammatory and chronic immune disor-
ders, including inflammatory bowel disease (IBD) [1].
IL-33, also known as IL-1F11, represents the most re-
cently identified member of the IL-1Family, which also
includes the classic cytokines IL-1α, IL-1β and IL-18.
IL-33 is a protein with a dual function that can act both as
a signaling cytokine as well as an intracellular nuclear fac-
tor, originally reported to be preferentially localized to the
high endothelial venules of human tonsils, Peyer’s patches
and lymph nodes [2]. More recent evidence suggests that* Correspondence: theresa.pizarro@case.edu
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reproduction in any medium, provided the orIL-33 is widely distributed throughout various organ sys-
tems in the body, primarily expressed in nonhematopoietic
cells, including fibroblasts, adipocytes, smooth muscle cells,
endothelial cells, bronchial and intestinal epithelial cells
(IEC) [3-5], but is also present in cells of hematopoietic
origin, particularly in restricted populations of professional
antigen-presenting cells, such as macrophages and den-
dritic cells [5].
IL-33 exerts its biological effects through binding to
its receptor, IL-1 receptor-like 1 (IL1RL1), also known as
ST2 [5,6]. In the presence of IL-33, ST2 pairs with
its coreceptor, the IL-1 receptor accessory protein
(IL-1RAcP), and allows signaling through mitogen-
activated protein kinase and NF-κB [5,7]. ST2 has
been reported to be constitutively expressed in mast
cells, as well as T helper (Th)2 lymphocytes in both
mice and humans [5,8,9].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Th2 immunity, based on the expression of its cell-bound
receptor, ST2L (IL-1R4), in polarized Th2 lymphocytes
and its ability to induce the production of Th2 cytokines
(for example, IL-4, IL-5 and IL-13), in both in vitro and
in vivo systems [5]. Moreover, exogenous administration
of recombinant IL-33 in mice led to Th2-mediated im-
mune responses, inducing eosinophilia, splenomegaly,
goblet cell hyperplasia and mucus production at mucosal
surfaces, and increased serum levels of IL-5 and IgE
[10]. IL-33 has been shown to be involved in airway in-
flammation [11-13], allergic reactions [14-16], and
rheumatic diseases [17,18], and also to reduce the devel-
opment of atherosclerosis through the induction of IL-5
[19]. IL-33, however, has also been described to exacer-
bate arthritis, widely considered a Th1/Th17-mediated
pathology [17,18].
In regard to its role in the gastrointestinal (GI) tract,
IL-33 appears to play a critical role in maintaining nor-
mal gut homeostasis. IL-33 has been shown to enhance
mucosal defenses against intestinal parasites and bacteria,
as described for Toxoplasma gondii [20], Pseudomonas
aeruginosa [21] and Leptospira [22] infection, indicating a
primary role of protection. Elevated expression of IL-33
has also been reported in the inflamed mucosa of IBD
patients, mainly in ulcerative colitis (UC), and to a lesser
extent, in Crohn’s disease (CD) patients [23-26]. Although
these initial studies suggest a pathogenic role for IL-33 in
IBD, the specific localization of subepithelial myofibro-
blasts (SEMFs) below ulcerative lesions in UC, but not in
CD, patients, indicate the potential role for IL-33 in
wound/ulcer healing [24].
In fact, aside from its elicitation of mounting a potent
Th2 immune response, emerging evidence supports the
possible role of the IL-33/ST2 axis in modulating wound
healing and fibrosis. Fibrosis is commonly believed to
represent the end stage of the repair process during
chronic and/or relapsing tissue damage, wherein inflam-
matory cell infiltration and resident fibroblast activation
persists, while the reparative ability of mesenchymal
stem cells is diminished. Heart failure and cardiac fibro-
sis have been reported to be associated with the produc-
tion of IL-33 from cardiac fibroblasts [27], while ST2
and transforming growth factor beta (TGFβ) have been
shown to be increased in a model of bleomycin-induced
lung fibrosis [28]. Additionally, in a mouse model of
liver fibrosis induced by carbon tetrachloride, adminis-
tration of an ST2-Fc fusion protein was found to in-
crease Th2 cytokine production and enhance hepatic
fibrosis [29].
Taken together, there is clear evidence of the IL-33/
ST2 axis in maintaining normal gut homeostasis, par-
ticularly in promoting mucosal wound healing and re-
pair. When dysregulated, this important ligand-bindingpair can also play a critical role in the progression of
chronic inflammation and fibrosis, leading to such GI-
related disorders as IBD. The purpose of this review is
to explore the role of IL-33 in modulating epithelial re-
pair, mucosal healing, and fibrosis in the GI tract during
normal gut homeostasis and in the setting of chronic in-
testinal inflammation. We will also touch upon the po-
tential link between IL-33/ST2 in the process of
tumorigenesis and GI-related cancer, an alternate out-
come when uncontrolled and/or dysregulated epithelial
proliferation occurs.
IL-33 in epithelial restoration/repair, mucosal healing, and
maintenance of normal gut homeostasis
The GI tract, with its epithelial barrier consisting of a
total surface area of approximately 200 m2, is man’s
most widely exposed organ system to the external envir-
onment. The intestinal barrier represents a functional
unit responsible for two main tasks crucial for survival
of the individual: allowing nutrient absorption, and
defending the body from penetration of unwanted, often
dangerous, macromolecules. The gut mucosa is a multi-
layer system consisting of an external ‘anatomical’ bar-
rier and an inner ‘functional’ immunological barrier.
Commensal gut microbiota, a mucous layer, and the in-
testinal epithelial monolayer constitute the anatomical
barrier. The deeper, inner layer consists of a complex
network of immune cells organized in a specialized and
compartmentalized system known as ‘gut-associated
lymphoid tissue’ or GALT. GALT represents both iso-
lated and aggregated lymphoid follicles and is one of the
largest lymphoid organs, containing up to 70 % of the
body’s total number of immunocytes, and is involved in
responding to pathogenic microorganisms and in pro-
viding immune tolerance to commensal bacteria. The
ability of GALT to interact with the luminal antigens
rests on specific mucosal immune cells (that is, dendritic
cells and M cells), primarily localized to Peyer’s patches
within the ileum, that are intimately positioned at the
mucosal-environmental interface and internalize micro-
organisms and macromolecules. These specialized im-
mune cells have the ability to present antigen to naïve T
lymphocytes, which subsequently produce cytokines and
activate mucosal immune responses, when needed. The
interaction of these components sustains the mainten-
ance of the delicate equilibrium of intestinal homeosta-
sis. Many factors can alter this balance, including
alterations in the gut microflora, modifications of the
mucus layer, and epithelial damage, leading to increased
intestinal permeability and translocation of luminal con-
tents to the underlying mucosa. The integrity of these
structures is necessary for the maintenance of normal
intestinal barrier function and dysregulation of any of
the aforementioned components have been implicated
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disorders, including infectious enterocolitis, irritable
bowel syndrome, small intestinal bowel overgrowth, and
allergic food intolerance [30-32].
Emerging evidence indicates a paramount role for
IL-33 in the maintenance of gut mucosal homeostasis.
Like IL-1α, IL-33 appears to serve as a dual function
protein. Full-length, unprocessed IL-33 contains a nu-
clear localization sequence and a DNA-binding do-
main [33] that has been shown to be constitutively
localized to the nucleus of epithelial, as well as endo-
thelial, cells [4]. Under normal conditions, IL-33 can act
as an intracellular nuclear factor [2] that, upon inflamma-
tory stimuli, is released from the cell through a currently
unknown mechanism and behaves as a functional,
secreted cytokine [33]. One of the earliest observations
regarding the biological activity of IL-33 is its ability to
promote epithelial proliferation and mucus production
[5], which are obvious functions involved in epithelial res-
titution and repair, as well as overall mucosal wound heal-
ing and protection. In addition, and similar to IL-1α,
increasing evidence indicates that IL-33 can function as
a prototypic ‘alarmin’, passively released upon cellular
damage, stress, or necrosis, and able to serve as a dan-
ger signal/alarmin to alert the immune system of a local
threat, such as trauma or infection [4,34-36]. In this set-
ting, IL-33 has the ability to signal local, innate immune
responses in an effort to mount an effective, physio-
logical inflammatory reaction in order to restore normal
gut homeostasis.
IBD pathogenesis and the IL-33/ST2 axis
In IBD, characterized by chronic, relapsing inflammation
with global epithelial barrier dysfunction and persistent
leakiness [37,38], efficient mucosal healing is one of the
most prominent clinical needs to be addressed and goals
to be achieved in order for patients to maintain long-
term remission [39]. On the other hand, the repair
process involves the orchestration of several different in-
testinal mucosal cell populations that, during chronic
and persistent tissue damage, may result in the gener-
ation of excessive connective tissue deposition and the
development of fibrosis.
It is now well established and confirmed by several
groups that increased IL-33 expression is associated with
IBD when compared to healthy controls, particularly in
UC patients [23-26]. Gut mucosal expression of IL-33 is
primarily localized to nonhematopoietic cells, particu-
larly IEC [23,25,26] and myofibroblasts [24]. In addition,
ex vivo studies on isolated intestinal mucosal cell popu-
lations and immunolocalization on full-thickness intes-
tinal tissues show that IL-33 is also expressed by a wide
variety of cell types [24,25,40], such as fibroblasts,
smooth muscle cells, endothelial cells [5,19], andadipocytes [3,25]. In active UC, IL-33 is localized to, and
potently expressed by, IEC, as well as infiltrating lamina
propria mononuclear cells, belonging to the monocyte/
macrophage and B cell lineages [23-25]. It has also been
originally reported by Kobori et al. [24], and later con-
firmed [40], that IL-33 is expressed in activated SEMFs
situated below ulcerative lesions in UC, but not in CD,
patients supporting a potential functional role for IL-33
in ulcer/wound healing, which may be different in UC
compared to CD.
Similar to IL-33, its receptor, ST2, is also increased in
the intestinal mucosa of IBD patients [23,25]. Import-
antly, the intestinal tissue expression pattern of ST2 is
different in healthy mucosa compared to that found in
chronically inflamed IBD patients, wherein ST2 is abun-
dantly expressed in macroscopically noninflamed colon
epithelium, while during chronic inflammatory processes
characterizing either UC or CD, its expression is lost/
decreased and redistributed [6]. This epithelial-derived
tissue expression for ST2 appears to be IBD-specific
since non-specific colitides (for example, diverticulitis
and infectious colitis) do not present with this same ex-
pression pattern [25].
Taken together, considering the potential role of IL-33
in promoting mucosal protection, as well as its tissue
distribution in IBD, it is tempting to speculate that the
primary role for IL-33 is, in fact, to induce epithelial
restitution and repair and mucosal healing. In addition,
further analysis has shown that the ST2 variant for
which expression is altered in the epithelium of IBD
patients is ST2L, IL-33's signaling transmembrane re-
ceptor [6,23]. As such, it is possible that impaired epi-
thelial ST2L expression, specifically in IBD patients,
may represent an inherent epithelial defect or a nega-
tive feedback response to chronic exposure of elevated
IL-33 concentrations. One cannot rule out, however,
that IL-33 may have pathogenic, as opposed to protect-
ive, effects on the epithelium, as well as consider its
effects on mucosal immune cell populations to induce
the infiltration of innate cells, specifically neutrophils
and eosinophils, and mount potent Th2, Th17, and po-
tentiate Th1 inflammatory responses. In fact, the di-
chotomous role of IL-33 as well as other innate-type
cytokines, including several members of the IL-1Family,
have been best characterized in the intestine, where they
can possess both protective and proinflammatory func-
tions, depending upon the immunological status of the
host and/or the type and phase of the ongoing inflamma-
tory process [6,41]. Investigation has turned to the use of
animal models of IBD to mechanistically address the spe-
cific role of the IL-33/ST2 axis in IBD (summarized in
Table 1) [17,18,27,28,42-47].
Dextran sodium sulphate (DSS)-induced colitis repre-
sents a T cell-independent, chemically induced model of
Table 1 Role of IL-33/ST2 axis in animal models of tissue repair and fibrosis
Target Organ/ System Animal Model Model Manipulation Proposed Role






Acute DSS colitis Genetic deletion
of IL-33
Pathogenic Neutrophil recruitment [42]
Exogenous IL-33
administration
Pathogenic Neutrophil recruitment [43,44]
Chronic DSS colitis Exogenous IL-33
administration
during recovery phase
Protective Th1→Th2 switch: improvement




TNBS colitis Exogenous IL-33
administration




SAMP1/YitFc mice Blockade of IL-33 by
anti-ST2 antibody
administration
Pathogenic Activation of pathogenic
IL-17-producing macrophages
Blockade of IL-33 by
anti ST2 antibody
administration





SAMP1/YitFc mice Blockade of IL-33 by
anti ST2 antibody
administration






















genetic deletion of ST2












Blockade of IL-33 by sST2
administration






Interruption of IL-33 signaling




Pathogenic Activation of pathogenic
mast cell [18]
Blockade of IL-33 by anti-ST2
antibody administration
Pathogenic Induction of IFNγ and
IL-17 [17]
Skin
Skin fibrosis BL/6 mice Exogenous IL-33
administration
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driven by innate immune responses. Studying the period
immediately after DSS administration (recovery phase) is
a useful way to also evaluate mechanism(s) of epithelialrepair and mucosal healing. Interestingly, investigation
into the role of IL-33 in the development of colitis using
this model has generated mixed results, and likely
reflects the dichotomous roles of IL-33 in both inducing
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repair and mucosal healing.
DSS administration to IL-33-deficient mice resulted in
less severe colitis than in wild-type (WT) controls, with
decreased granulocyte infiltration [42], while exogenous
administration of IL-33 to DSS-treated mice further
aggravated colitis and induced influx of neutrophils [44],
suggesting a pathogenic role of IL-33, at least in an acute
inflammatory setting. Although it is unclear as to what
factor(s) precisely regulate IL-33 in the gut, it has re-
cently been shown that severe colonic inflammation with
a marked increase in IL-33-producing macrophages
results after DSS administration to mice expressing a
truncated form of the receptor for TGFβ, supporting a
pathogenic function for IL-33 during acute colitis and
indicates a direct effect of TGFβ on macrophages to
limit IL-33 expression [48]. Imaeda et al. also reported
an exacerbation of DSS-induced colitis upon treatment
with IL-33, hypothesized to occur by IL-33-dependent
induction of pathogenic Th2 cytokines; although in the
same mice, IL-33 restored goblet cells that were found
to be depleted in IL-33-untreated mice [43]. In addition,
during the recovery phase of DSS-induced colitis, while
weight recovery was markedly delayed in IL-33 deficient
mice, no significant difference in colonic inflammation
was observed between these mice and WT littermates
[42]. The authors propose that in this particular model,
IL-33 plays an important role in driving acute, innate
immune responses, but is dispensable in the mainten-
ance of chronic intestinal inflammation. Alternatively,
the possibility exists that the delayed weight recovery
observed in IL-33-deficient mice, but not in WT litter-
mates, is due to the lack of IL-33-driven epithelial regen-
eration and restoration of barrier function leading to a
dampened ability for mucosal healing.
In fact, as opposed to their results obtained from IL-
33 treatment in acute DSS colitis, Groβ et al. showed
that IL-33 administration during repeated, chronic cyc-
ling of DSS caused a reduction of colitis, suppressed
interferon gamma (IFNγ), and decreased bacterial trans-
location [44], supporting a protective role of IL-33 that
the authors suggest may occur by switching from Th1-
to Th2-driven immune responses. These results are sup-
ported by a recent study using the trinitrobenzene sul-
fonic acid (TNBS)-induced model of colitis [45]. This
model represents another chemically induced model of
colonic inflammation that has been reported to elicit
Th1 immune responses, particularly if performed using
a chronic protocol [49]. Although the aforementioned
study utilized an acute, four-day protocol, exogenous ad-
ministration of IL-33 was shown to ameliorate TNBS-
induced colitis and induce the production of Th2-type
cytokines [45]. In addition, the protective effect of IL-33
was diminished after depletion of T-regulatory cells(Tregs). The authors propose that, mechanistically, IL-
33 has an indirect effect on the development of Foxp3+
Tregs by increasing the expression of epithelial-derived
thymic stromal lymphopoietin (TSLP) and retinoic acid,
which promotes the activation of CD103+ dendritic cells
[50] and leads to the induction of Foxp3+ Treg develop-
ment [51]. The ultimate IL-33-induced expansion of
Foxp3+ Tregs facilitates the observed decrease in the se-
verity of colitis.
Using a spontaneous murine model of Th1/Th2-
driven enteritis, that is, SAMP1/YitFc (SAMP) strain,
IL-33 expression patterns in the gut mucosa and within
the systemic circulation of IBD patients, were confirmed
[25]. Chronic intestinal inflammation localized to the
terminal ileum in SAMP mice occurs spontaneously,
without chemical, genetic or immunologic manipula-
tion, and is characterized by an early Th1 immune re-
sponse and a late, chronic phase of disease dominated
by Th2 cytokines [52,53]. IL-33 gut mucosal tissue
levels in SAMP mice were shown to progressively in-
crease over time and demonstrated a positive correl-
ation with ileal inflammation, with epithelial cells
exclusively expressing full-length IL-33 [25]. Although
the precise, mechanistic role of IL-33 has not yet been
addressed in the SAMP model, preliminary studies
blocking IL-33 signaling by administration of an anti-
body against ST2 indicate a pathogenic role during the
chronic phase of disease development [54,55]. In fact,
neutralization of IL-33 interfered with the massive in-
flux of eosinophils into the gut mucosa [55] and po-
tently decreased fibrosis and fibrogenic gene expression
[54], characteristic of SAMP mice. Interestingly, al-
though blockade of IL-33 had a significant effect on de-
creasing the overall severity of ileal inflammation in
SAMP mice, the magnitude of this reduction was ap-
proximately 30 %, which may reflect a need for optimiz-
ing treatment dosage or alternatively, represents an
opposing effect of interfering with epithelial repair and
mucosal healing. Investigation is further warranted to
study the role of IL-33 during the early, acute phase of
SAMP ileitis, as well as the specific role of epithelial-
derived IL-33 and IL-33's direct effects on the intestinal
epithelium.
The hypothesis that innate-type cytokines often pos-
sess dichotomous functions within the gut mucosa has
been alluded to earlier. This concept is most strongly
supported by members of the IL-1Family of cytokines in
the pathogenesis of IBD (Table 2) [23-26,40,41,56-63],
where the same cytokine can possess both classic proin-
flammatory properties as well as protective, anti-
inflammatory functions, which is dependent primarily
on the presence of receptor-bearing cells during a par-
ticular setting. As such, aside from the established proin-
flammatory properties of IL-1α, IL-1β, IL-18 and their
Table 2 Speculative role of IL-1 cytokine family members in tissue repair and fibrosis during inflammatory bowel
disease (IBD)




Disease association Speculative role in tissue
repair and fibrosis
IL –1α IL –1F1 IL –1R type I CD [56,57], UC [56,57] Protective during early phase of
inflammation [41]
IL–1β IL –1F2 IL –1R type I CD [56,57], UC [56,57] Protective during early phase of
inflammation [41]
IL –1Ra IL –1F3 IL –1R type I UC [58-60] Potential dual role [41]
IL–18 IL-1F4 IL-18Rα CD [61,62] Protective during early phase of
inflammation [41]
IL–36Ra IL –1F5 IL 1Rrp2 Unknown Unknown
IL–36α IL–1F6 IL–lRrp2 Unknown Unknown
IL –37 IL–1F7 IL–18Rα Unknown for human IBD,
antagonist for DSS colitis [63]
Protective (correlates with
breakdown of intestinal barrier) [63]
IL-36β IL-1F8 IL-1Rrp2 Unknown Unknown
IL-36γ IL-1F9 IL-1Rrp2 Unknown Unknown
IL–38 IL–1F10 IL 1Rrp2 Unknown Unknown
IL- 33 IL –1F11 ST2 UC [23-26] Protective [40,41]
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MyD88, emerging evidence indicates that the same pro-
teins are necessary for the maintenance of mucosal
homeostasis by effectively handling microbiota, as well
as by protecting and restoring the integrity of the epithe-
lial barrier [64-66]. The current literature regarding
the role of IL-33 in IBD is at present ambiguous, at
best; however, it may reflect another example of an
innate-type cytokine that possesses multiple functions
depending on the immunological status and genetic sus-
ceptibility of the host. While one of the first observa-
tions of IL-33-dependent epithelial proliferation and
mucus production in the gut [5] suggests the promotion
of mucosal repair and healing, dysregulated or uncon-
trolled IL-33 production may lead to the more patho-
genic features characteristic of IBD, including epithelial
barrier dysfunction, chronic, relapsing inflammation, and
formation of fibrotic lesions.
Emerging role of IL-33 in fibrosis
The concept that fibrosis occurs as the end result of
dysregulated wound healing is well established. Th2
cytokines, such as IL-4 and IL-13, have been reported
to be important factors in the development of fibrosis
[67-69] and collagen synthesis [70,71]. Relevant to the
present review, IL-33 was originally described as a po-
tent inducer of the Th2 cytokines, IL-4 and IL-13, by
CD4+ T lymphocytes [5], and administration of recom-
binant IL-33 into WT mice increased local tissue levels
of IL-4, IL-5, and IL-13 in the liver [46]. In fact, ex-
pression of IL-33 and its receptor/coreceptor, ST2/IL-
1RAcP, has been associated with both murine and
human liver fibrosis, with a direct correlation betweenIL-33 and ST2 levels, but not IL-1RAcP, and the sever-
ity of fibrosis. Moreover, IL-33 levels have been shown
to closely correlate to collagen synthesis in both mouse
and human livers during chronic injury [46]. Liver
endothelial and hepatic stellate cells (HSCs) constitute
the major sources of IL-33 in liver fibrosis, and the in-
crease in IL-33 mRNA levels are likely due to the acti-
vation and proliferation of HSCs and/or the increased
number of endothelial cells [46]. T lymphocytes appear
to be a primary target for soluble IL-33 as they repre-
sent a large percentage of ST2-positive cells that are
present in human fibrotic livers [72] and are crucial
for the development of fibrosis [5,67-69]. As such, it is
likely that IL-33-dependent fibrogenesis in the liver
involves the production of IL-33 by activated HSCs
that subsequently act on ST2-bearing T cells, stimulat-
ing profibrogenic Th2 cytokines to initiate the process
of fibrosis [46].
IL-33 is also considered to be a novel factor involved
in the pathogenesis of pancreatic fibrosis as a conse-
quence of chronic pancreatitis [73]. Fibrosis of the pan-
creas is one of the representative histopathologic
findings in cases of chronic pancreatitis where pancre-
atic myofibroblasts play a crucial role. Nishida et al. re-
cently reported that human pancreatic myofibroblasts
are both a source of IL-33 as well as express the IL-33
receptor complex of ST2L/IL-1RAcP [73]. In this study,
IL-33 secretion is potently induced through a mitogen-
activated protein kinase (MAPK)-dependent activator
protein-1 (AP-1) pathway by IL-1β, TNF, and LPS, while
ST2L expression is upregulated by IL-4 and IFNγ by ac-
tivation of STAT6 and STAT1, respectively. IL-33 was
shown to enhance the expression of proinflammatory
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fibroblasts and to stimulate the proliferation and migra-
tion of these cells [73].
Although the role of IL-33 has not yet been fully
investigated in the pathogenesis of intestinal fibrosis,
several lines of evidence indicate that the IL-33/ST2 axis
may represent an important mediator in this process.
Within the gut mucosa, SEMFs have been reported as a
primary source of IL-33, specifically in UC patients
where they are situated below ulcerative mucosal lesions
[24,40]. In fact, Sponheim et al. observed that a promin-
ent feature of IBD-associated IL-33 expression is the ac-
cumulation of both fibroblasts and myofibroblasts in
ulcerations of UC lesions [40]. Although, the association
and localization of IL-33-producing SEMFs with muco-
sal ulcerations suggests an important role in wound
healing, one cannot rule out its potential role in gut-
associated fibrosis, particularly in the setting of cycling
of chronic tissue damage and repair, characteristic of
IBD. In addition, the GI tract represents the largest
organ interfacing with the external environment and
interacting with luminal antigens, infectious agents, and
other components of the gut microbiota. Interestingly,
toll-like receptor (TLR)3, TGFβ, and mechanical strain
have been shown to promote the development of myofi-
broblasts from connective tissue fibroblasts in wound re-
pair [74,75], wherein fibroblasts acquire α-smooth
muscle actin-containing stress fibers in order to success-
fully achieve wound contraction and healing [76]. Con-
trary to its effects on gut-associated macrophages [48],
TGFβ was shown to boost TLR3-dependent induction of
IL-33 in cultured fibroblasts [40]. TLR3 signals the pres-
ence of virus-derived double stranded RNA, but mRNA
released from damaged or necrotic epithelial cells can
also lead to TLR3 activation, which has been shown to
protect against DSS-induced colitis [77]. Based on its
similarity to the physiological wound healing seen in the
skin [40], the recruitment of IL-33-positive fibroblasts to
ulcers is considered a protective process driven by the
loss of the epithelial barrier and by the presence of the
gut microflora that acquires a critical role in modulating
mucosal healing. Interestingly, subcutaneous administra-
tion of IL-33 to WT mice has been shown to lead to the
accumulation of inflammatory cells and the development
of skin fibrosis, which is dependent on IL-13 and the
presence of eosinophils [47]. Eosinophils and their de-
granulation have, in fact, been implicated in the process
of fibrosis in several organ systems, including the GI
tract [78]. Although a direct correlation has not yet been
established between eosinophilia and fibrosis in the
SAMP model of chronic intestinal inflammation, prelim-
inary studies have demonstrated that IL-33 represents
a critical factor important in the development of both
processes [54,55].Potential link between IL-33 and GI-related cancer
Based on the established role of IL-1Family members,
including IL-1β and IL-18, in GI-related cancers, the
possibility exists that IL-33 can likewise play an import-
ant role in GI-associated tumor formation. In fact, a re-
cent study has reported elevated IL-33 levels in the
serum of gastric cancer patients that correlated with sev-
eral poor prognostic factors, including depth of invasion,
distant metastasis, and advanced stage, but not with the
classic tumor markers, CEA and CA 19–9 [79]. Of note,
however, no significant difference in IL-33 expression
was found between four gastric cancer cell lines and the
normal gastric cell line, GES-1, which may indicate that
IL-33 expression can either be modulated by local envir-
onmental factors and/or produced by other cells
responding to gastric cancer epithelial cells. As such, the
initial observation of increased, circulating IL-33 levels
in gastric cancer patients may be related to the progres-
sion of the cancer. In addition, based on IL-33's ability
to shift host immune responses to a Th2 phenotype,
downregulation of tumor-specific immune responses can
occur by inhibiting tumor antigen presentation [80,81].
From this point of view, IL-33 may represent one of the
effective weapons tumor cells utilize in order to create
an ideal environment for obtaining optimal growth con-
ditions. IL-33 has also been reported to be elevated in
lung tissues of K-ras transgenic mice [82], which are
prone to tumorigenesis and cancer, in endothelial cells
from several distinct human tumors, and in cancer epi-
thelial cell lines [4,83]. Furthermore IL-33 is able to acti-
vate NF-κB that has been implicated in the development
of several types of human cancers [84,85], and is a com-
mon transcription factor involved in signaling of several
IL-1Family members. Finally, in a recent report, suppres-
sion of breast cancer progression and metastasis was
observed in a murine breast cancer model wherein mice
lacked the IL-33 signaling receptor, ST2 [86], further
supporting the role of the IL-33/ST2 axis in tumor for-
mation and the progression of cancer.
Conclusions
The present review provides evidence that, aside from
its central role as a classic proinflammatory cytokine
promoting Th2 immune responses, IL-33 also plays a
critical role in modulating epithelial repair, mucosal
healing, and fibrosis in the GI tract during normal gut
homeostasis and in the setting of chronic intestinal in-
flammation (summarized in Figure 1). Although less
developed, a potential association between IL-33/ST2
in the process of tumorigenesis and GI-related cancer
may also exist. Based on this new information, novel
pathogenic hypotheses can be formed that have
important translational implications in regard to



















Figure 1 Working hypothesis of IL-33's dichotomous role in the gut mucosa. Damage of the epithelium (for example, ulcer formation) and
other proinflammatory stimuli, including pathogen-associated molecular patterns (PAMPs) derived from luminal antigens and the local intestinal
microflora, induce intracellular IL-33 expression that is subsequently released by necrotic intestinal epithelial cells (IECs) as a potential alarmin.
Depending on the presence and abundance of ST2-bearing target cells and the phase of disease process, IL-33 may have very different effects
within the gut mucosa. IL-33 may act on various immune cell populations, including macrophages, and T and B cells, eliciting proinflammatory
effects and promoting Th2 immune responses. Concomitantly, IL-33 can also induce epithelial proliferation and repair and overall wound healing
by acting directly or indirectly on IEC and subepithelial myofibroblast (SEMFs). Alternatively, chronic mucosal damage, granulomatous
inflammation, and dyregulated activation of mesenchymal cells, such as SEMFs and fibroblasts, can lead to fibrosis and the formation of intestinal
fibrotic lesions.
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play a potential role in sustaining tumor growth, by
modulating host immune responses against tumor cells
and/or in the recruitment of SEMFs to support their
growth. Further mechanistic studies will clarify the
precise physiologic and pathophysiologic role of IL-33
in the GI tract.Abbreviations
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